321 related articles for article (PubMed ID: 17644456)
1. Melanin biosynthesis in Madurella mycetomatis and its effect on susceptibility to itraconazole and ketoconazole.
van de Sande WW; de Kat J; Coppens J; Ahmed AO; Fahal A; Verbrugh H; van Belkum A
Microbes Infect; 2007 Jul; 9(9):1114-23. PubMed ID: 17644456
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting DHN- and DOPA-melanin biosynthesis pathway increased the therapeutic value of itraconazole in Madurella mycetomatis infected Galleria mellonella.
Lim W; Konings M; Parel F; Eadie K; Strepis N; Fahal A; Verbon A; van de Sande WWJ
Med Mycol; 2022 Feb; 60(2):. PubMed ID: 35064672
[TBL] [Abstract][Full Text] [Related]
3. In vitro antifungal activity of isavuconazole against Madurella mycetomatis.
Kloezen W; Meis JF; Curfs-Breuker I; Fahal AH; van de Sande WW
Antimicrob Agents Chemother; 2012 Nov; 56(11):6054-6. PubMed ID: 22964246
[TBL] [Abstract][Full Text] [Related]
4. The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo.
Konings M; Eadie K; Strepis N; Nyuykonge B; Fahal AH; Verbon A; van de Sande WWJ
Med Mycol; 2023 Nov; 61(11):. PubMed ID: 37960934
[TBL] [Abstract][Full Text] [Related]
5. Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents.
van de Sande WW; Fahal AH; Bakker-Woudenberg IA; van Belkum A
Antimicrob Agents Chemother; 2010 Jun; 54(6):2738-40. PubMed ID: 20350944
[TBL] [Abstract][Full Text] [Related]
6. Epidemiological cut-off values for itraconazole and ravuconazole for Madurella mycetomatis, the most common causative agent of mycetoma.
Nyuykonge B; Siddig EE; Mhmoud NA; Nyaoke BA; Zijlstra EE; Verbon A; Bakhiet S; Fahal AH; van de Sande WWJ
Mycoses; 2022 Dec; 65(12):1170-1178. PubMed ID: 36005544
[TBL] [Abstract][Full Text] [Related]
7. Combining two antifungal agents does not enhance survival of Galleria mellonella larvae infected with Madurella mycetomatis.
Eadie K; Parel F; Helvert-van Poppel M; Fahal A; van de Sande W
Trop Med Int Health; 2017 Jun; 22(6):696-702. PubMed ID: 28342219
[TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-Bis(2-methoxy-4-nitro-5- sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay.
Ahmed AO; van de Sande WW; van Vianen W; van Belkum A; Fahal AH; Verbrugh HA; Bakker-Woudenberg IA
Antimicrob Agents Chemother; 2004 Jul; 48(7):2742-6. PubMed ID: 15215141
[TBL] [Abstract][Full Text] [Related]
9. Development and Validation of an
Abd Algaffar SO; Verbon A; van de Sande WWJ; Khalid SA
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318015
[TBL] [Abstract][Full Text] [Related]
10. In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine.
van Belkum A; Fahal AH; van de Sande WW
Antimicrob Agents Chemother; 2011 Apr; 55(4):1771-3. PubMed ID: 21263050
[TBL] [Abstract][Full Text] [Related]
11. Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim.
Lim W; Eadie K; Konings M; Rijnders B; Fahal AH; Oliver JD; Birch M; Verbon A; van de Sande W
J Antimicrob Chemother; 2020 Apr; 75(4):936-941. PubMed ID: 31904836
[TBL] [Abstract][Full Text] [Related]
12. New species of Madurella, causative agents of black-grain mycetoma.
de Hoog GS; van Diepeningen AD; Mahgoub el-S; van de Sande WW
J Clin Microbiol; 2012 Mar; 50(3):988-94. PubMed ID: 22205798
[TBL] [Abstract][Full Text] [Related]
13. Eumycetoma.
Estrada R; Chávez-López G; Estrada-Chávez G; López-Martínez R; Welsh O
Clin Dermatol; 2012; 30(4):389-96. PubMed ID: 22682186
[TBL] [Abstract][Full Text] [Related]
14. Testing of the in vitro susceptibilities of Madurella mycetomatis to six antifungal agents by using the Sensititre system in comparison with a viability-based 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5- [(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay and a modified NCCLS method.
van de Sande WW; Luijendijk A; Ahmed AO; Bakker-Woudenberg IA; van Belkum A
Antimicrob Agents Chemother; 2005 Apr; 49(4):1364-8. PubMed ID: 15793113
[TBL] [Abstract][Full Text] [Related]
15. In vitro antifungal susceptibility of coelomycete agents of black grain eumycetoma to eight antifungals.
Ahmed SA; de Hoog GS; Stevens DA; Fahal AH; van de Sande WW
Med Mycol; 2015 Apr; 53(3):295-301. PubMed ID: 25631481
[TBL] [Abstract][Full Text] [Related]
16. Amphotericin B but not itraconazole is able to prevent grain formation in experimental Madurella mycetomatis mycetoma in mice.
van de Sande WW; van Vianen W; ten Kate M; Fahal A; Bakker-Woudenberg I
Br J Dermatol; 2015 Dec; 173(6):1561-2. PubMed ID: 26150103
[No Abstract] [Full Text] [Related]
17. Antimycotic susceptibility testing of agents of black grain eumycetoma.
Venugopal PV; Venugopal TV; Ramakrishna ES; Ilavarasi S
J Med Vet Mycol; 1993; 31(2):161-4. PubMed ID: 8389847
[TBL] [Abstract][Full Text] [Related]
18. Madurella mycetomatis is highly susceptible to ravuconazole.
Ahmed SA; Kloezen W; Duncanson F; Zijlstra EE; de Hoog GS; Fahal AH; van de Sande WW
PLoS Negl Trop Dis; 2014 Jun; 8(6):e2942. PubMed ID: 24945848
[TBL] [Abstract][Full Text] [Related]
19. The safety and efficacy of itraconazole for the treatment of patients with eumycetoma due to Madurella mycetomatis.
Fahal AH; Rahman IA; El-Hassan AM; Rahman ME; Zijlstra EE
Trans R Soc Trop Med Hyg; 2011 Mar; 105(3):127-32. PubMed ID: 21247608
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Disc Diffusion, Etest, and a Modified CLSI Broth Microdilution Method for
Nyuykonge B; van Amelsvoort L; Eadie K; Fahal AH; Verbon A; van de Sande W
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0043321. PubMed ID: 34181477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
